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Abstract: An organic extract from fresh shrimp (Litopenaeus vannamei) was studied for 
antimutagenic and antiproliferative properties using Salmonella typhimurium tester strains 
TA98 and TA100 with metabolic activation (S9) and a cancer cell line (B-cell lymphoma), 
respectively. Shrimp extract was sequentially fractionated by thin layer chromatography 
(TLC) and each fraction was tested for antimutagenic and antiproliferative activities. Crude 
organic  extracts  obtained  from  shrimp  reduced  the  number  of  revertants  caused  by 
aflatoxina B1, showing a dose-response type of relationship. Sequential TLC fractionation 
of  the  active  extracts  produced  several  antimutagenic  and/or  antiproliferative  fractions. 
These results suggested that the lipid fraction of the tested species contained compounds 
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with chemoprotective properties that reduce the mutagenicity of AFB1 and proliferation of 
a cancer cell line. 
Keywords: antimutagenicity; antiproliferation; cultured shrimp 
 
1. Introduction 
During the last two decades several kinds of chemical mutagens and carcinogens have been found 
to be present in food. Some of them are food contaminants such as mycotoxins, pesticides, etc., and 
some others are present in food as a consequence of the processes applied to them (e.g., pyrolysates, 
nitrosamines,  policyclic  aromatic hydrocarbons,  etc.) [1]. However, in  our diet, a  great  variety  of 
compounds have been found to have properties that are beneficial for the consumer. Among the types 
of  “functional”  compounds  found  in  food  are  anti-cholesterolemic  compounds,  antioxidants, 
antiviral, etc.,  including  antimutagenic  and  antiproliferative  agents.  These  compounds  include 
thiocyanates, indole-3-carbinol, allyium compounds, linoleic acid (also found as conjugated linoleic 
acid),  polyunsaturated  fatty  acids,  caffeic  acid  phenethyl  ester  (CAPE)  and  flavonoids  such  as 
pinocembrin, rutin, naringenin, and hesperetin, respectively [2].  
Omega-3 and omega-6 fatty acids are components of lipid fraction of fish that have been associated 
with the prevention of cardiovascular diseases and cancer [3–5]. These fatty acids are structurally 
similar  to  linoleic  and  linolenic  acids,  which  have  been  shown  to  be  antimutagenic  and 
anticarcinongenic [3,6,7]. Based on these facts, this research work attempted to detect the presence of 
antimutagenic and antiproliferative compounds in shrimp, a highly consumed seafood, worldwide. 
2. Results and Discussion 
2.1. Antimutagenicity  
Shrimp  tail  muscle  was  extracted  and  fractionated  using  TLC,  and  the  fractions  obtained 
(Scheme 1) were tested for antimutagenicity. The antimutagenic potential of the fractions that were 
selected for further fractionation are shown in Figures 1 and 2. After first TLC procedure (TLC 1) 
fractions RA, RB, and RC were obtained. Antimutagenicity testing showed all extracts to have an 
inhibitory effect on the mutagenicity of 500 ng of AFB1 for both tester strains suggesting the presence 
of antimutagenic compounds in all of them. Fraction B was selected for further fractionation, as it 
showed a well defined dose-response type of relationship. After second TLC isolation procedure, three 
fractions were obtained from RB (Scheme 1). Fraction RB2 (Rf = 0.18–0.78) decreased the reversion 
rate  achieved  by  500  ng  AFB1  suggesting  that  antimutagenic  compounds  were  contained  in  this 
fraction. Although other fractions also decreased reversion caused by AFB1, dose-response type of 
relationships were not as consistent in both tested strains as that observed for RB2.  Mar. Drugs 2010, 8                       
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Scheme 1. Schematic for separation and isolation of antimutagenic fractions from shrimp. 
Numbers in parentheses are Rf values. 
      Shrimp muscle sample 
 
      CHCl3 (1:5 w/v) extracted, filtered and evaporated to dryness 
 
Preparative TLC 1 
         (CHCl3-acetone 9:1 v/v) 
 
 
          RA              RB           RC 
   (0.00–0.29)       (0.29–0.69)               (0.69–1.0) 
 
Preparative TLC 2      
 
 
         RB1                       RB2                          RB3 
   (0.00–0.18)             (0.18–0.78)               (0.78–1.00) 
 
Preparative TLC 3                                                                                                           
    
RB21             RB22           RB23            RB24              RB25 
          (0.0–0.06)       (0.35–0.60)       (0.63–0.78)         (0.78–0.84)          (0.84–1.00) 
 
Preparative TLC 4                                                                                                     
 
 
      RB231                   RB232                      RB233 
                                       (0.00–0.23)             (0.23–0.74)               (0.74–1.00) 
      
Preparative TLC 5                                                                                                     
 
 
                   RB2321                 RB2322                    RB2323 
                                       (0.00–0.48)             (0.48–0.78)               (0.78–1.00) 
 
Preparative TLC 6                                                                                                     
 
 
                  RB23221                                           RB23222 
                              (0.88–0.94)                            (0.94–1.00) Mar. Drugs 2010, 8                       
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Therefore, RB2 was selected for further fractionation. After the third TLC isolation procedure, five 
fractions were obtained from RB2 (Scheme 1). Antimutagenic testing performed on these fractions 
showed that fractions RB23 differed from the rest having effectively inhibited the mutagenicity of 
AFB1  induced in  both  tester strains.  RB23 was selected for further fractionation. Fractionation of 
RB23 (TLC 4) resulted in three regions, RB231, RB232, and RB233. Antimutagenesis testing revealed 
that fraction RB232 more efficiently decreased tester strains reversion rate than RB231 and RB233, 
showing  a  dose-response  relationship  with  a  lower  slope.  Therefore,  RB232  was  selected  and 
fractionated by means of a TLC 5 procedure. TLC 5 developed in only two fractions that were named 
RB2321 and RB2322. The antimutagenicity assay performed, showed RB2322 as the fraction that 
inhibited the mutagenicity of AFB1 in both tester strains, and its contents were fractionated using a 
sixth TLC procedure. TLC 6 applied to RB2322 resulted in only two bands, RB23221 and RB23222. 
The contents from these bands were extracted and tested for antimutagenicity. Results from this assay 
showed  that  both  bands  contained  compounds  that  inhibited  the  mutagenicity  of  AFB1  in  a 
dose-response  type  of  relationship.  The  contents  from  both  bands  were  subjected  to  further  TLC 
procedures using a different solvent system without successful fractionation. 
Figure 1. Antimutagenic potential of most active fractions sequentially isolated from white 
shrimp.  Salmonella  test  strain  TA98  was  exposed  to  different  concentrations  of  the 
fractions obtained throughout the fractionation procedure. All values represent mean of 
triplicate determinations ±  standard deviation.  
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Figure 2. Antimutagenic potential of most active fractions sequentially isolated from white 
shrimp.  Salmonella  test  strain  TA100  was  exposed  to  different  concentrations  of  the 
fractions obtained throughout the fractionation procedure. All values represent mean of 
triplicate determinations ±  standard deviation. 
Extract dilution (times diluted)
1e-3 1e-2 1e-1 1e+0
R
eve
rta
nts/
pla
te
0
200
400
600
800
1000
1200
1400
1600
1800
RB
RB2
RB23
RB232
RB2322
RB23221
 
2.2. Antiproliferative activity 
In  order  to  investigate  the  presence  of  antiproliferative  agents  in  shrimp  lipidic  extract,  a 
fractionation procedure parallel to that carried out for antimutagens was performed (Scheme 2). 
The  fractions  RA,  RB  and  RC  obtained  from  the  first  TLC  fractionation  were  tested  on  the 
antiproliferative assays. All shrimp fractions showed antiproliferative activity on the murine cancer 
cell  line  M12.C3.F6  (B-cell  lymphoma)  in  a  concentration-dependent  manner  (Figure  3A–C). 
However, only fractions RA and RC were able to inhibit the cellular proliferation beyond 50%, at the 
lowest doses tested (12.5 and 25 μg/mL). The highest level of cellular proliferation inhibition was 
observed for fraction RA (above 95% for the second lowest dose tested (25 μg/mL); therefore, this 
shrimp fraction was selected for further fractionation). 
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Scheme  2.  Schematic  for  separation  and  isolation  of  antiproliferative  fractions  from 
shrimp. Numbers in parentheses are Rf values. 
        Shrimp muscle sample 
      CHCl3 (1:5 w/v) extracted, filtered and evaporated to dryness 
            Preparative TLC 1 
                                                          (CHCl3-acetone 9:1 v/v) 
 
       RA                          RB      RC 
(0.00–0.29)       (0.29–0.69)             (0.69–1.0) 
Preparative TLC 2 
    
                     RA1                        RA2                         RA3 
          (0.00–0.26)              (0.26–0.68)              (0.68–1.00) 
 
Preparative TLC 3                                                                                                           
    
 
RA31                RA32                 RA33 
          (0.0–0.13)                                  (0.63–0.84)               (0.84–1.00) 
      
Preparative TLC 4                                                                                                           
    
            RA331                         RA332 
         (0.0–0.19)                                                          (0.77–1.00) 
Preparative TLC 5                                                                                                           
    
    RA3321             RA3322              RA3323 
   (0.0–0.09)                                 (0.75–0.87)            (0.87–1.00) 
 
Preparative TLC 6                                                                                                           
    
 
          RA33231             RA33232              RA33233 
         (0.0–0.06)                                    (0.06–0.33)              (0.88–1.00) 
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Figure  3.  Antiproliferative  effect  of  lipidic  extracts  from  white  shrimp  on  murine 
cancerous cell lines. Murine cancer M12.C3.F6 cell lines were treated with different dose 
lipidic extracts during 48 h. Cellular proliferation was determined by standard MTT assay 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide).  The  results  shown  are 
representative from at least three independent experiments. All values represent mean of 
triplicate  determinations  ±   standard  deviation.  Significant  differences  (P  <  0.05)  from 
control cell cultures are marked with an asterisk. Control cell cultures were incubated with 
DMSO (0.5%). 
 
From the second TLC fractionation step, fractions RA1 (Rf = 0.00–0.26), RA2 (Rf = 0.26–0.68), 
and  RA3  (Rf  =  0.68–1.0)  were  obtained  (Scheme  2)  and  tested  for  antiproliferation  activity 
(Figure 3D–F). Fractions RA1 and RA2 were able to inhibit cellular proliferation up to 20% at the 
highest dose tested (100 μg/mL). However, a 60% cellular proliferation inhibition was observed in 
cancer cell cultures exposed to fraction RA3; therefore, this fraction was selected to continue with the 
fractionation process. Figure 4A–D shows the antiproliferative activities of shrimp fractions obtained 
from subsequent TLC fractionation (TLC 3, TLC 4, and TLC 5) of fraction RA3. All fractions derived 
from RA3 had significant inhibitory effect on the growth of the cancer cell line M12.C3.F6 tested. In 
contrast, RA3-derived fractions showed a low antiproliferative effect on the murine non-cancerous cell 
line L-929 (Figure 4E–H).  Mar. Drugs 2010, 8                       
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Figure 4. Antiproliferative effect of lipidic extracts from white shrimp on murine cancer 
and non-cancerous cell lines. Murine cancer M12.C3.F6 (A, B, C y D) and non cancerous 
L-929 (E, F, G y H) cell lines were treated with different dose lipidic extracts during 48 h. 
Cellular proliferation was determined by standard MTT assay (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide). The results shown are representative from at least 
three independent experiments. All values represent mean of triplicate determinations ±  
standard deviation. Significant differences (P < 0.05) from control cell cultures are marked 
with asterisk. Control cell cultures were incubated with DMSO (0.5%). 
 
In previous studies performed in our laboratory, we have detected the presence of antimutagenic 
compounds in yellowtail fish (Seriola lalandi), lisa fish (Mugil cephalus), and cazon fish (Mustelus 
lunulatus)  [8].  Chemical  components  of  marine  organisms  have  been  associated  to  a  variety  of 
chemopreventive properties. Omega-3 polyunsaturated fatty acids (n-3PUFAs) have been implicated in 
chemoprevention of cancer [5,9,10]. Omega-3 PUFAs have been associated with cancerous tumor 
growth suppression [11,12] and reduced risk of prostate cancer [13,14]. Mar. Drugs 2010, 8                       
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Therefore, the current research focused on the isolation of compound(s) present in a lipidic extract 
from shrimp that would cause an inhibition of the mutagenicity of AFB1 or cellular proliferation of 
cancer cell lines, or both. All fractions obtained after the first fractionation step decreased the number 
of revertants per plate in a dose-response type of relationship in both tester strains, suggesting the 
presence of antimutagens in every fraction. All of the fractions were able to cause an inhibition of 
AFB1 mutagenicity close to 50%, even at the highest dilution tested. At this point, we could have 
selected any of the fractions to continue with the isolation process. However, for both strains, the lower 
number of revertants/plate was observed for fraction RB, suggesting that contents from this fraction 
might have a higher potency in inhibiting the mutagenicity of AFB1; therefore, RB was selected for 
further  fractionation.  Additional  studies  on  the  antimutagenic  properties  of  fractions  RA  and  RC 
are recommended. 
Fraction RB was fractionated into another three groups of bands coded as RB1, RB2, and RB3 
(Scheme 1).  Antimutagenesis  testing  performed  on  the  extracts  from  these  fractions  showed  that 
fraction RB2 (Figures 1 and 2) had the most consistent dose-response type of relationship in both tester 
strains. Fractions such as RB1 and RB3 partially inhibited the mutagenicity of AFB1 towards both 
tester strains; however, they fail to show a dose-response type of relationship. However, these results 
may suggest the presence of antimutagenic compounds which are minor components of fraction RB or 
have less antimutagenic potency than those contained in fractions RB2. Based on the dose-response 
relationship and antimutagenic potency, fractions RB2 was selected for further fractionation. 
Fraction RB2 was separated into five bands which were also tested for antimutagenicity. From the 
five extracts obtained and tested, fractions RB23 caused the highest inhibition of AFB1 mutagencity 
(more than 50% AFB1 inhibition was achieved with undiluted RB23 for both tester strains) showing a 
dose-response type of relationship. Fractions RB22, RB24, and RB25 showed antimutagenicity when 
undiluted; however, this activity was lost upon first dilution. A possible reason for this apparent loss of 
antimutagenicity after the third step in the fractionation process is the possible existence of synergistic 
antimutagenic compounds that may loss their antimutagenic properties when separated. However, the 
possible loss of material throughout the fractionation process is not discounted. Based on the above, 
the fractionation of RB23 proceeded. The contents of RB23 were fractionated into three regions on the 
TLC plate: RB231 (Rf = 0.00–0.18), RB232 (Rf = 0.18–0.78), and RB233 (Rf = 0.78–1.0). Results 
from the antimutagenicity assay showed that RB232 inhibited AFB1 to a greater extent than the other 
two fractions. These results suggested that antimutagenic compounds were concentrated in this fraction 
located  in  the  middle  portion  of  the  TLC  plate.  The  contents  of  this  fraction  were  extracted  and 
subjected to a fifth TLC procedure in order to continue with the isolation of antimutagenic compounds 
from shrimp. TLC 5, RB232 was then divided into two fractions, RB2321 and RB2322. Although both 
fractions showed antimutagenic potential, contents from RB2322 inhibited AFB1 mutagenicity in both 
tester  strains  showing  a  consistent  dose-response  type  of  relationship.  The  sixth  TLC  procedure 
applied to RB2322 resulted in another two fractions, RB23221 and RB23222. Contents from both 
fractions were localized in the upper portion of the plate, showing their affinity for the solvent used 
(CHCl3-acetone 9:1). Both were antimutagenic, showing similar dose-response relationships, which 
suggest the presence of at least two compounds with similar antimutagenic characteristics. Attempts to 
fraction both, RB23221 and RB23222 using different solvents system were unsuccessful, suggesting Mar. Drugs 2010, 8                       
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that the chemical nature of the compounds contained in both fractions are similar. Further studies on 
the chemical/structural characterization of RB23221 and RB23222 are under way. 
As mentioned before, three regions (RA, RB, and RC) were obtained from the fractionation of the 
lipidic extract from shrimp. Fraction RB was the most antimutagenic; however, all fractions showed 
antiproliferative activity, with RA and RC being the fractions that had the highest inhibition of cancer 
cell proliferation (Figure 3). These results suggest that all three fractions contained both, antimutagens 
and antiproliferative compounds; however, this investigation focused on the search for the compounds 
with the most potent activities. Fractions RA and RC inhibited murine cancer cell proliferation in a 
dose-dependent manner; however, at the lowest dose tested (12.5 μg/mL), fraction RA inhibited more 
than 50% of cell proliferation compared to the control. Therefore, RA was considered the most potent 
antiproliferative fraction and was selected for further fractionation. 
Of the three fractions derived from fraction RA (RA1, RA2, and RA3), neither RA1 nor RA2 were 
able to significantly inhibit murine cancerous cell proliferation. However, fraction RA3 at a dose of 
100 μg/mL inhibited more than 60% of cell proliferation compared to the control (Figure 3F). These 
results suggest that antiproliferative compound(s) of fraction RA were partitioned to fraction RA3, 
therefore this was subjected to additional TLC procedures.  
From the third TLC fractionation step (fraction RA3), three fractions (RA31, RA32, and RA33) 
were obtained, of which fraction RA33 showed the highest inhibition of cancer cell proliferation (close 
to 90%). This might suggest that components with this type of biological activity were isolated in this 
fraction and possibly separated from other interfering compounds. However, further studies are needed 
in order to characterize these active fractions.  
Lipidic fractions from white shrimp substantially delayed the growth of the murine cancer cell 
M12.C3.F6, but the growth of normal murine cell line L-929 was considerably less affected. These 
observations suggest that active constituents of white shrimp have a preferential antiproliferative effect 
on cancer cell lines. 
2.3. Partial chemical/structural characterization studies 
To investigate the presence of functional  groups and structural features, that may contribute  to 
elucidate the chemical/structural nature of the bioactive compounds present in both antimutagenic and 
antiproliferative fractions from shrimp, FT-IR and 
1H NMR studies were carried out. When bioactive 
fractions were analyzed by 
1H NMR, the spectra obtained showed broad peaks located in the 1.3 ppm 
region; these signals are attributed to the presence of methylenic protons from long chain fatty acids, 
such as those present in -3 fatty acids. Additional contributions from lipid resonances (0.9–1.7 ppm 
region) are also present, where the wide peak at 0.9 ppm region is associated to methyl groups [17]. 
FT-IR spectroscopy performed on bioactive fractions from shrimp resulted in spectra that coincided in 
a typical signal for carbonyl function group; the peaks located in the 1600–1680 range could be related 
to the unsaturated hydrocarbons featuring C=C, with attached hydrogens. The C-H stretch vibrations at 
2900 cm
-1 can be attributed to methylenic groups; this is in agreement with results from NMR which 
suggest  the  presence  of  fatty  acids.  In  addition,  the  spectrum  of  both  the  antimutagenic  fraction 
(RB23221) and the antiproliferative fraction (RA33233), showed a typical signal of hydroxyl group 
above 3000 cm
-1; this is also in accordance with a fatty acid structure.  Mar. Drugs 2010, 8                       
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Figure  5. 
1H  NMR  spectra  (CDCl3/TMS) of antimutagenic fraction  RB23221  (a), and 
antiproliferative  fraction  RA33233  (b);  both  obtained  from  a  lipidic  extract  from 
white shrimp. 
 
 
Figure  6.  FT-IR  spectra  of  antimutagenic  fraction  RB23221  (a),  and  antiproliferative 
fraction RA33233 (b), both obtained from a lipidic extract from white shrimp. 
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3. Experimental Section 
3.1. Testing species 
Shrimp (Litopenaeus vannamei) was obtained from Bahí a de Kino, Sonora, Mé xico (approximately 
2000 km northwest Mé xico City, Mé xico) and transported in ice to the University of Sonora Seafood 
Laboratory. Edible portions of shrimp were separated, fresh-packed, and stored at –25 ° C until needed 
for further analysis.  
Shrimp extract 
A 100 g portion of shrimp muscle and five parts of CHCl3 were homogenized in a blender at high 
speed for 1 min. Resulting mix was poured into a flask and agitated during 30 min with the aid of a 
Wrist Action Burrel Shaker (Burrel Corporation, Pittsburg, PA, U.S.). The mix was filtered through 
Whatman No. 4 filter paper with vacuum and the filtrate was evaporated to dryness under N2 stream.  
3.2. Fractionation of shrimp extract 
The fractionation of shrimp extract was performed according to Burgos-Herná ndez et al. [8]. A 
2.0 mL aliquot of shrimp muscle extract was applied onto a 1.0 mm thick silica gel coated preparative 
TLC plate and developed with chloroform-acetone (9:1 v/v). Fluorescent bands, identified with their 
Rf, were scraped off the plate and the silica gel was extracted with 2 ×  25 mL chloroform-methanol-
acetone  (9:1:1  v/v/v).  Extracts  were  re-suspended  and  serially  diluted  in  DMSO  and  tested  for 
antimutagenicity  and  antiproliferation.  When  either  antimutagenic  or  antiproliferative  bands  were 
detected, their contents were obtained again from a fresh muscle sample following the same procedure 
and were subjected to further fractionation (Schemes 1 and 2). 
3.3. Bacterial cultures 
Salmonella typhimurium TA98 and TA100 were kindly provided by Dr. B. N. Ames, Department of 
Biochemistry (University of California at Berkeley, CA, U.S.). Fresh overnight tester strain cultures, to 
which DMSO was added as cryoprotective agent, were stored at –80 ° C. Tester strains were checked 
routinely  to  confirm  genetic  features  using  the  procedure  described  by  Maron  and  Ames  [15]. 
Metabolic  activation  system  S9  mix  (Aroclor  1254-induced,  Sprague-Dawley  male  rat  liver 
in 0.154 M KCl solution) was purchased from Molecular Toxicology, Inc. (Annapolis, MD, U.S.) and 
stored at −80 ° C. 
3.4. Antimutagenicity test 
Dry  extracts,  obtained  either  directly  from  shrimp  or  from  preparative-TLC  fractionation  of 
extracts,  were  reconstituted  and  serially  diluted  with  DMSO,  and  were  spiked  with  pure  AFB1 
(Sigma-Aldrich, St. Louis, MO, U.S.) to a final concentration of 500 ng of AFB1/100 µL. Residual 
mutagenicity of AFB1  was  assayed using the  standard plate incorporation procedure described by 
Maron and Ames [15]. Different AFB1 concentrations were used as a control for both tester strains. All 
assays were performed in triplicate. Mar. Drugs 2010, 8                       
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3.5. Cell lines 
Cell lines  NCTC clone L929 (normal  subcutaneous  connective tissue)  was  purchased from the 
American Type Culture Collection (ATCC, Rockville, MD, U.S.). The M12.C3.F6 (murine B-cell 
lymphoma)  cell  line  was  kindly  provided  by  Dr.  Emil  R.  Unanue  (Department  of  Pathology  and 
Immunology,  Washington  University  in  St.  Louis,  MO,  U.S.).  All  cell  cultures  were  cultured  in 
Dulbecco’s  modified  Eagle’s  medium  (DMEM)  supplemented  with  5%  heat  inactivated  fetal  calf 
serum and grown at 37 ° C in an atmosphere of 5% CO2. 
3.6. Antiproliferation assay 
To evaluate the effect of shrimp crude extracts and their fractions on the proliferation of different 
cancer  cell  lines,  cell  proliferation  was  determined  using  the  standard  MTT  assay 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide)  [16].  Briefly,  10,000  cells  (50  μL) 
were plated in each well of a flat 96 well plate. After 12 h incubation at 37 ° C in an atmosphere of 5% 
CO2 to allow cell attachment, the cell cultures were incubated with 50 µL of medium containing 
various concentrations of either crude extract or fraction, and the cell cultures were incubated for 48 h. 
The crude extract or fraction was first pre-suspended in DMSO and then diluted in DMEM media. 
Control cell cultures were incubated with DMSO (final concentrations of DMSO 0.06–0.5%). Control 
cell cultures did not show any evidence of cell damage. In the last 4 h of the cell culture, 10 µL of 
MTT  stock  solution  (5  mg/mL)  were  added  to  each  well  [16].  Formazan  crystals  formed  were 
dissolved with acidic isopropanol, and the plates were read in an ELISA plate reader (Benchmark 
Microplate Reader, Bio-Rad, Hercules, CA, U.S.), using a test wavelength of 570 nm and a reference 
wavelength of 630 nm. Plates were normally read within 15 minutes of adding isopropanol. Data were 
analyzed using analysis of variance (ANOVA) with Tukey-Kramer and Duncan´ s multiple comparison 
tests (Number Cruncher Statistical Software (NCSS 2000). 
3.7. Partial chemical/structural characterization studies 
To obtain information that may contribute to a partial chemical/structural characterization of the 
compounds  contained  in  the  bioactive  fractions,  Fourier  Transform  Infrared  (FT-IR)  and  nuclear 
magnetic  resonance  (
1H  NMR)  studies  were  performed.  For  FT-IR  spectroscopy,  thin  films  were 
formed with samples from the bioactive fractions on ZnSe cells and spectra were obtained using a GX 
Perkin Elmer equipment. To obtain the nuclear magnetic resonance spectra, bioactive fractions were 
dissolved in CDCl3 and analyzed in a Bruker ADVANCE 400 spectrometer using tetramethylsilane 
(TMS) as a reference. 
4. Conclusions 
Additional studies need to be conducted to define and characterize, at the chemical and biochemical 
level, the preferential effect of shrimp fractions on murine cancer cell lines. Results from this study 
suggest that there are various groups of compounds in the lipid fraction of shrimp that are biologically 
active against either the mutagenicity of AFB1 or murine cancerous cell proliferation, or against both. 
Although  n-3PUFAs  may  be  considered  as  factors  partially  responsible  for  the  antimutagenicity Mar. Drugs 2010, 8                       
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observed in  the first  fractions  obtained in  this  study, the isolation and identification of the actual 
antimutagens in fish is the focus of our ongoing research. 
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